Indivior Pharmaceuticals
INDV
338 hedge funds and large institutions have $4.98B invested in Indivior Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 115 increasing their positions, 109 reducing their positions, and 36 closing their positions.
173% more call options, than puts
Call options by funds: $106M | Put options by funds: $39M
147% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 36
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
28% more capital invested
Capital invested by funds: $3.89B → $4.98B (+$1.09B)
17% more funds holding
Funds holding: 290 → 338 (+48)
6% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 109
5.25% less ownership
Funds ownership: 104.82% → 99.58% (-5.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$116M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$55.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$41.9M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$37.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$90.6M |
| 2 |
Goldman Sachs
New York
|
-$62.1M |
| 3 |
DM
Deerfield Management
New York
|
-$52.6M |
| 4 |
MAP
Madison Avenue Partners
New York
|
-$52.3M |
| 5 |
TSC
Two Seas Capital
Rye,
New York
|
-$46M |
INDV Hedge Fund Activity: Q2 2026 in Review
338 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q2 2026, worth a combined $4.98B — up 28% from $3.89B a quarter earlier.
Buyers outnumbered sellers: 89 funds opened new INDV positions and 36 closed out — a net gain of 53 holders — while 115 added to existing stakes and 109 trimmed.
The largest buyer was Franklin Resources, adding an estimated $116M. The largest seller was Millennium Management, cutting an estimated $90.6M.
- 338 institutional investors held Indivior Pharmaceuticals (INDV) as of Q2 2026, up from 290 in Q1 2026.
- Funds reported $4.98B of Indivior Pharmaceuticals stock for Q2 2026, up 28% quarter-over-quarter.
- 89 funds opened new Indivior Pharmaceuticals positions in Q2 2026 and 36 closed out, a net change of +53 holders.
- The largest Indivior Pharmaceuticals buyer in Q2 2026 was Franklin Resources, an estimated $116M added.
- The largest Indivior Pharmaceuticals seller in Q2 2026 was Millennium Management, an estimated $90.6M sold.
Based on aggregated 13F filings for Q2 2026.